CY1110349T1 - Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη - Google Patents
Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμηInfo
- Publication number
- CY1110349T1 CY1110349T1 CY20101100698T CY101100698T CY1110349T1 CY 1110349 T1 CY1110349 T1 CY 1110349T1 CY 20101100698 T CY20101100698 T CY 20101100698T CY 101100698 T CY101100698 T CY 101100698T CY 1110349 T1 CY1110349 T1 CY 1110349T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hpv
- dough
- vlps
- synthetic
- protein
- Prior art date
Links
- 108700042300 human papillomavirus type 52 L1 Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 230000007969 cellular immunity Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000005030 transcription termination Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 210000005253 yeast cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55592604P | 2004-03-24 | 2004-03-24 | |
| EP05725933A EP1730175B1 (en) | 2004-03-24 | 2005-03-18 | Optimized expression of hpv 52 l1 in yeast |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110349T1 true CY1110349T1 (el) | 2015-04-29 |
Family
ID=34964085
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100698T CY1110349T1 (el) | 2004-03-24 | 2010-07-26 | Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη |
| CY2015052C CY2015052I1 (el) | 2004-03-24 | 2015-12-07 | Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY2015052C CY2015052I1 (el) | 2004-03-24 | 2015-12-07 | Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7700103B2 (enExample) |
| EP (1) | EP1730175B1 (enExample) |
| JP (1) | JP4833962B2 (enExample) |
| KR (1) | KR101203403B1 (enExample) |
| CN (1) | CN1934131B (enExample) |
| AR (1) | AR048191A1 (enExample) |
| AT (1) | ATE466022T1 (enExample) |
| AU (1) | AU2005230907C1 (enExample) |
| BE (1) | BE2015C066I2 (enExample) |
| BR (1) | BRPI0509079B8 (enExample) |
| CA (1) | CA2560487C (enExample) |
| CY (2) | CY1110349T1 (enExample) |
| DE (1) | DE602005020913D1 (enExample) |
| DK (1) | DK1730175T3 (enExample) |
| ES (1) | ES2343255T3 (enExample) |
| FR (1) | FR15C0085I2 (enExample) |
| HU (1) | HUS1500062I1 (enExample) |
| IL (1) | IL178140A (enExample) |
| LT (2) | LTC1730175I2 (enExample) |
| LU (1) | LU92903I2 (enExample) |
| MY (1) | MY148656A (enExample) |
| NL (1) | NL300777I1 (enExample) |
| NO (3) | NO338055B1 (enExample) |
| NZ (1) | NZ549898A (enExample) |
| PL (1) | PL1730175T3 (enExample) |
| PT (1) | PT1730175E (enExample) |
| RU (1) | RU2373219C2 (enExample) |
| SI (1) | SI1730175T1 (enExample) |
| TW (1) | TWI349036B (enExample) |
| WO (1) | WO2005097821A1 (enExample) |
| ZA (1) | ZA200607575B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
| CN1869215B (zh) * | 2006-05-19 | 2012-07-04 | 长春百克生物科技股份公司 | 一种制备人乳头瘤病毒的病毒样颗粒的方法 |
| AU2008226974B2 (en) | 2007-03-09 | 2013-08-15 | Merck Sharp & Dohme Llc | Papillomavirus vaccine compositions |
| CN101440371B (zh) * | 2007-11-23 | 2012-09-05 | 上海泽润生物科技有限公司 | 一种16型人乳头状瘤病毒主要衣壳蛋白l1基因 |
| WO2009076824A1 (zh) | 2007-11-23 | 2009-06-25 | Shanghai Zerun Biotechnology Co., Ltd. | 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途 |
| US8623375B2 (en) * | 2010-05-14 | 2014-01-07 | Baxter International Inc. | Chimeric OspA genes, proteins, and methods of use thereof |
| CA2799205A1 (en) | 2010-05-25 | 2011-12-01 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically-truncated probes |
| CN102268076B (zh) * | 2010-07-02 | 2017-04-26 | 厦门大学 | 截短的人乳头瘤病毒52型l1蛋白 |
| US8361720B2 (en) * | 2010-11-15 | 2013-01-29 | Exact Sciences Corporation | Real time cleavage assay |
| EP2646559A2 (en) | 2010-12-03 | 2013-10-09 | MS Technologies, LLC | Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells |
| CN102154325B (zh) * | 2011-01-01 | 2013-08-21 | 上海生物制品研究所有限责任公司 | 针对人乳头瘤状病毒的疫苗及其制法和用途 |
| RU2445357C1 (ru) * | 2011-02-15 | 2012-03-20 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16 |
| RU2445358C1 (ru) * | 2011-02-15 | 2012-03-20 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18 |
| CN110484554B (zh) * | 2013-04-26 | 2024-04-16 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv52 l1蛋白的方法 |
| CN104164374B (zh) * | 2013-05-17 | 2019-10-22 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv31 l1蛋白的方法 |
| WO2015057541A1 (en) | 2013-10-16 | 2015-04-23 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
| CN104878022A (zh) * | 2015-04-27 | 2015-09-02 | 段青姣 | 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用 |
| CN106701796B (zh) * | 2015-08-12 | 2021-11-16 | 北京康乐卫士生物技术股份有限公司 | 52型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
| CN109750049B (zh) * | 2017-11-07 | 2023-08-18 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒52亚型蛋白表达 |
| US12673103B2 (en) | 2020-02-14 | 2026-07-07 | Merck Sharp & Dohme Llc | HPV vaccine |
| CN114539365B (zh) * | 2020-11-26 | 2023-12-01 | 中国医学科学院基础医学研究所 | 一种改造的人乳头瘤病毒52型l1蛋白及其用途 |
| CN113073105B (zh) * | 2021-03-23 | 2023-06-13 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
| CN113549634B (zh) * | 2021-06-07 | 2023-03-31 | 郑州大学 | 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用 |
| WO2023014853A1 (en) | 2021-08-06 | 2023-02-09 | Merck Sharp & Dohme Llc | Hpv vaccine |
| AR126813A1 (es) | 2021-08-19 | 2023-11-15 | Merck Sharp & Dohme Llc | Nueva nanopartícula lipídica termostable y métodos de uso de la misma |
| CR20250529A (es) | 2023-06-09 | 2026-01-12 | Merck Sharp & Dohme Llc | Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1339729C (en) * | 1988-10-26 | 1998-03-17 | Wayne D. Lancaster | Human papillomavirus type 52 dna sequences and methods for employing thesame |
| US5821087A (en) | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
| IL117591A0 (en) | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
| EE9900343A (et) | 1997-02-07 | 2000-02-15 | Merck & Co., Inc. | Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon |
| CA2296067C (en) | 1997-07-09 | 2008-10-07 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
| DE69933875T2 (de) | 1998-08-14 | 2007-05-31 | Merck & Co., Inc. | Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt. |
| EP1105466B1 (en) * | 1998-08-14 | 2006-04-26 | Merck & Co., Inc. | Process for purifying human papillomavirus virus-like particles |
| SE514982C2 (sv) * | 1999-09-30 | 2001-05-28 | Active Biotech Ab | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning |
| ES2233437T3 (es) * | 1999-08-25 | 2005-06-16 | MERCK & CO., INC. | Genes sinteticos del papilomavirus optimizados para expresion en celulas humanas. |
| US6436402B1 (en) | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
| NZ523683A (en) | 2000-07-21 | 2004-08-27 | Glaxo Group Ltd | Codon-optimized papilloma virus sequences |
| US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| RU2356943C2 (ru) | 2003-03-24 | 2009-05-27 | Мерк Энд Ко., Инк. | Молекула нуклеиновой кислоты, кодирующая hpv31 l1, экспрессирующий вектор, клетка-хозяин, вирусоподобная частица и способ ее получения, вакцина, фармацевтическая композиция и способы с их использованием |
| MY140664A (en) * | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
| MY139500A (en) * | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
-
2005
- 2005-03-18 AT AT05725933T patent/ATE466022T1/de active
- 2005-03-18 JP JP2007505032A patent/JP4833962B2/ja not_active Expired - Lifetime
- 2005-03-18 ES ES05725933T patent/ES2343255T3/es not_active Expired - Lifetime
- 2005-03-18 EP EP05725933A patent/EP1730175B1/en not_active Expired - Lifetime
- 2005-03-18 BR BRPI0509079A patent/BRPI0509079B8/pt not_active IP Right Cessation
- 2005-03-18 PL PL05725933T patent/PL1730175T3/pl unknown
- 2005-03-18 TW TW094108431A patent/TWI349036B/zh active
- 2005-03-18 CN CN2005800095956A patent/CN1934131B/zh not_active Expired - Lifetime
- 2005-03-18 KR KR1020067019673A patent/KR101203403B1/ko not_active Expired - Lifetime
- 2005-03-18 DE DE602005020913T patent/DE602005020913D1/de not_active Expired - Lifetime
- 2005-03-18 DK DK05725933.5T patent/DK1730175T3/da active
- 2005-03-18 MY MYPI20051180A patent/MY148656A/en unknown
- 2005-03-18 PT PT05725933T patent/PT1730175E/pt unknown
- 2005-03-18 RU RU2006137363/13A patent/RU2373219C2/ru active
- 2005-03-18 CA CA2560487A patent/CA2560487C/en not_active Expired - Lifetime
- 2005-03-18 AU AU2005230907A patent/AU2005230907C1/en active Active
- 2005-03-18 SI SI200531052T patent/SI1730175T1/sl unknown
- 2005-03-18 WO PCT/US2005/009199 patent/WO2005097821A1/en not_active Ceased
- 2005-03-18 US US10/594,064 patent/US7700103B2/en active Active
- 2005-03-18 NZ NZ549898A patent/NZ549898A/en not_active IP Right Cessation
- 2005-03-23 AR ARP050101174A patent/AR048191A1/es active IP Right Grant
-
2006
- 2006-09-11 ZA ZA200607575A patent/ZA200607575B/xx unknown
- 2006-09-17 IL IL178140A patent/IL178140A/en active IP Right Grant
- 2006-10-23 NO NO20064815A patent/NO338055B1/no active Protection Beyond IP Right Term
-
2009
- 2009-10-14 US US12/578,995 patent/US7744892B2/en not_active Expired - Lifetime
-
2010
- 2010-07-26 CY CY20101100698T patent/CY1110349T1/el unknown
-
2015
- 2015-11-30 NL NL300777C patent/NL300777I1/nl unknown
- 2015-12-02 HU HUS1500062C patent/HUS1500062I1/hu unknown
- 2015-12-04 FR FR15C0085C patent/FR15C0085I2/fr active Active
- 2015-12-07 CY CY2015052C patent/CY2015052I1/el unknown
- 2015-12-08 LT LTPA2015050C patent/LTC1730175I2/lt unknown
- 2015-12-08 LU LU92903C patent/LU92903I2/xx unknown
- 2015-12-08 LT LTPA2015050D patent/LTPA2015050I1/lt unknown
- 2015-12-09 BE BE2015C066C patent/BE2015C066I2/nl unknown
-
2017
- 2017-01-20 NO NO2017005C patent/NO2017005I1/no unknown
-
2022
- 2022-11-30 NO NO2022050C patent/NO2022050I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1113875T1 (el) | Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα | |
| AR045804A1 (es) | Expresion optimizada de l1 del vph45 en levaduras | |
| Perenkov et al. | In vitro transcribed RNA-based platform vaccines: past, present, and future | |
| TW200602490A (en) | Optimized expression of HPV 52 L1 in yeast | |
| FR15C0079I2 (fr) | Expression optimisee de hpv 31 l1 dans la levure | |
| PL1685243T3 (pl) | Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów | |
| CY1117401T1 (el) | Πρωτεϊνες συντηξης αλβουμινης | |
| BRPI0407233A (pt) | Anticorpo neutralizante, molécula de anticorpo, anticorpo enxertado em cdr, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção da molécula de anticorpo, e, composição farmacêutica | |
| ATE284898T1 (de) | Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind | |
| WO2021176397A3 (en) | Expression of sars-cov proteins, nucleic acid constructs, virus like proteins (vlps) and methods relevant thereto | |
| MX2024002010A (es) | Vacunas terapeuticas contra el virus del papiloma. | |
| CY1110005T1 (el) | Γρανζυμο β ως ενας επαγωγεας αποπτωσης κυτταρων ογκων εξαρτωμενος απο ενα hsp70/hsp70 πεπτιδιο | |
| WO2002097062A3 (en) | Recombinant narbonolide polyketide synthase | |
| CY1105555T1 (el) | Ανθρωπινα πολυπεπτιδια pellino | |
| WO2023097319A9 (en) | Compositions and methods for inducing esr1, pi3k, her2, and her3 immune responses | |
| WO2006038129A3 (en) | Hepatitis c virus replication system | |
| CO2024013755A2 (es) | Composiciones y métodos para la prevención y el tratamiento de la infección por el virus de la rabia | |
| EP0789563A4 (en) | VACCINES AGAINST HEPATITIS VIRUS | |
| WO2025052108A3 (en) | Rna molecule | |
| WO2002044204A3 (en) | Cell-free assembly of lentiviral capsids | |
| RU2355764C2 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBMC-RT(А)-hum ДЛЯ ЭКСПРЕССИИ БЕЛКА ОБРАТНОЙ ТРАНСКРИПТАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА | |
| TH82139B (th) | การแสดงออกที่ถูกทำให้เหมาะสมของ hpv 45l1 ในยีสต์ | |
| RU2335540C1 (ru) | ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pBMC-nef(A)-hum | |
| Souza et al. | Peptide cleavage from different phenylmethylamine-resins | |
| MY138895A (en) | Optimized expression of hpv 31 l1 in yeast |